Health & Pharma Intelligence

Cancer Can Emerge from Epigenetic Change Rather than DNA Mutation

Liver cancer can arise from epigenetic changes via YAP1-TEAD-TET1 activation without nuclear DNA mutations.

Research relevance Informs preclinical cancer epigenetics research, potential grant directions in translational oncology, and teaching on alternative tumorigenic mechanisms beyond DNA mutations.

Brief: Researchers developed a mouse model of hepatocellular carcinoma (HCC) driven by YAP1-TEAD activation in hepatocytes, absent canonical driver gene mutations. Bisulfite sequencing showed widespread DNA demethylation and oncogene activation; Tet1 knockdown reduced HCC formation. Findings align with elevated signatures in hepatocytes from Fontan-associated liver disease patients, who develop HCC with fewer typical mutations.

Joint association of LDL cholesterol and inflammation with mortality and the modifying effect of physical activity: findings from two population-based cohort studies

Joint LDL-C and inflammation levels associate with higher all-cause and CVD mortality, modifiable by physical activity.

Research relevance Informs faculty research and teaching on modifiable CVD risk factors, supports grant development in metabolic inflammation and lifestyle interventions, and aids clinical/pharmaceutical research on preventive strategies.

Brief: Population-based cohorts from NHANES and CLHLS show combined low/high LDL-C with elevated inflammation markers (SII/PLR) link to increased mortality risks in general, ASCVD, and NCD populations. Physical activity significantly attenuates these associations. Restricted cubic splines, Cox models, and mediation analyses support the findings across 20,991 participants.

An Anti-Senescence Vaccine Increases Mouse Lifespan

Late-life senolytic vaccine reduced senescence markers and extended median lifespan by 12% in female mice.

Research relevance Highlights translational potential of senescence-targeting vaccines for longevity research, grant development in healthy ageing, and updates to teaching on pharmaceutical interventions for healthspan.

Brief: A three-element senolytic vaccine administered in late life to female B6 mice lowered senescence markers and increased median lifespan by 12%. The study highlights immune-mediated clearance of senescent cells but notes complications from short-lived controls. This provides preclinical evidence for senescence-targeting immunotherapies in ageing.

MRI study of 14,031 adults ties sleep to belly fat

Large MRI study links sleep efficiency to lower visceral fat and altered brain volumes in 14,031 adults.

Research relevance Informs faculty research and grant development in precision nutrition, metabolism, and longevity medicine by highlighting sleep as a modifiable factor in visceral fat accumulation and brain health.

Brief: Prenuvo and UT Dallas researchers analysed self-reported sleep data and whole-body MRI scans from 14,031 adults. Higher sleep efficiency correlated with reduced visceral abdominal fat and greater parietal gray matter volume. Self-reported sleep exceeding eight hours was associated with smaller hippocampal volume.

FDA clears NeuroXT’s AI tool that sizes up Alzheimer’s risk

FDA grants 510(k) clearance to NeuroXT’s NEXT-Cue AI tool for assessing Alzheimer’s progression risk in MCI patients.

Research relevance Highlights advancing AI applications in neurodegenerative disease evaluation, relevant for clinical pharmacy research, regulatory science teaching, and potential grant development in digital health tools for dementia.

Brief: NeuroXT’s NEXT-Cue, an AI-based Software as a Medical Device, integrates brain MRI, demographic data, and cognitive scores to provide supplementary information for clinicians evaluating mild cognitive impairment patients’ risk of progressing to Alzheimer’s dementia within five years. The tool received Class II 510(k) clearance from the FDA. It leverages routinely collected clinical data without requiring additional hardware.

Knowledge, attitudes, and practices toward artificial intelligence in pharmacy education and practice among pharmacy students and faculty in Bangladesh: a cross-sectional study

Cross-sectional KAP survey reveals moderate AI readiness among Bangladeshi pharmacy students and faculty, with faculty showing higher knowledge but limited institutional support.

Research relevance Highlights predictors of AI attitudes for curriculum integration, faculty development programmes, and potential grant opportunities in digital health education within LMIC pharmacy contexts.

Brief: A multi-institutional study of 447 pharmacy students and faculty in Bangladesh found faculty had significantly higher AI knowledge scores than students. Knowledge correlated moderately with positive attitudes; prior exposure and workshops predicted better attitudes. Participants expressed willingness for national AI guideline development despite funding gaps and privacy concerns.

Eisai to unveil five-year Alzheimer’s drug data at CTAD 2026

Eisai to present five-year lecanemab data and real-world studies at CTAD 2026.

Research relevance Provides extended clinical and real-world safety, biomarker and administration data for lecanemab that can inform faculty research, grant development and teaching on disease-modifying therapies in neurodegenerative disorders.

Brief: Eisai will share five-year treatment findings from the Clarity AD core and extension phases of lecanemab at the 19th Clinical Trials on Alzheimer’s Disease conference in November 2026. The programme includes a LEADER symposium, five oral presentations and 19 posters addressing safety, biomarkers, co-pathology, subcutaneous administration and post-discontinuation durability in early Alzheimer’s disease. Additional real-world evidence from the LEADER multicenter retrospective study in US clinical settings will be reported.

Each article is evaluated by an AI model on five dimensions totalling 0–25. The score reflects the quality and relevance of the evidence — not the importance of the topic alone. Articles are ranked and filtered before appearing in this briefing.